PMID- 31146420
OWN - NLM
STAT- PubMed-not-MEDLINE
LR  - 20201001
IS  - 2077-0383 (Print)
IS  - 2077-0383 (Electronic)
IS  - 2077-0383 (Linking)
VI  - 8
IP  - 6
DP  - 2019 May 29
TI  - Second-Line Gemcitabine Plus Nab-Paclitaxel for Patients with Unresectable 
      Advanced Pancreatic Cancer after First-Line FOLFIRINOX Failure.
LID - 10.3390/jcm8060761 [doi]
LID - 761
AB  - FOLFIRINOX (FX) and gemcitabine (GEM) plus nab-paclitaxel (GnP) have been 
      reported as effective regimens for unresectable advanced pancreatic cancer (APC). 
      FX may be more effective but is also associated with more adverse events (AEs). 
      Therefore, first-line treatment with FX followed by second-line GnP may be 
      appropriate. AIMS: To assess the safety and efficacy of second-line GnP for 
      patients with APC after first-line FX failure. METHODS: This study was a 
      multicenter prospective phase II study evaluating second-line GnP in patients 
      with APC after failed first-line FX. The primary endpoint was response rate (RR), 
      and the secondary endpoints were overall survival (OS), progression free survival 
      (PFS), and the frequency and degree of adverse events (AEs). RESULTS: Thirty 
      patients (14 male; median age, 64 years) were enrolled. The RR was 13.3%, with a 
      median follow-up time of 9.3 months. The median OS and PFS were 7.6 and 3.8 
      months, respectively. From the beginning of first-line treatment, the median OS 
      and PFS were 14.2 and 9.3 months, respectively. Grade 3 or 4 AEs were seen in 70% 
      of patients. CONCLUSION: Second-line GnP after FX failure for patients with APC 
      could be more effective than GEM alone. Further comparison studies are warranted.
FAU - Mita, Naoki
AU  - Mita N
AD  - First Department of Internal Medicine, Gifu University Hospital, 1-1 Yanagido, 
      Gifu 501-1194, Japan. mitanao8@yahoo.co.jp.
FAU - Iwashita, Takuji
AU  - Iwashita T
AUID- ORCID: 0000-0003-4978-1787
AD  - First Department of Internal Medicine, Gifu University Hospital, 1-1 Yanagido, 
      Gifu 501-1194, Japan. takuji@w7.dion.ne.jp.
FAU - Uemura, Shinya
AU  - Uemura S
AD  - First Department of Internal Medicine, Gifu University Hospital, 1-1 Yanagido, 
      Gifu 501-1194, Japan. ueshin550621@gmail.com.
FAU - Yoshida, Kensaku
AU  - Yoshida K
AD  - First Department of Internal Medicine, Gifu University Hospital, 1-1 Yanagido, 
      Gifu 501-1194, Japan. kensakuyoshidaky@gmail.com.
FAU - Iwasa, Yuhei
AU  - Iwasa Y
AD  - First Department of Internal Medicine, Gifu University Hospital, 1-1 Yanagido, 
      Gifu 501-1194, Japan. festinalenteyu@gmail.com.
FAU - Ando, Nobuhiro
AU  - Ando N
AD  - Department of Gastroenterology, Gifu Prefectural General Medical Center, Gifu 
      500-8717, Japan. nobuhiro5091ando@yahoo.co.jp.
FAU - Iwata, Keisuke
AU  - Iwata K
AD  - Department of Gastroenterology, Gifu Prefectural General Medical Center, Gifu 
      500-8717, Japan. keisukeiwata@nifty.com.
FAU - Okuno, Mitsuru
AU  - Okuno M
AUID- ORCID: 0000-0001-8989-6437
AD  - Department of Gastroenterology, Gifu Municipal Hospital, Gifu 500-8513, Japan. 
      mkobdkl@yahoo.co.jp.
FAU - Mukai, Tsuyoshi
AU  - Mukai T
AD  - Department of Gastroenterology, Gifu Municipal Hospital, Gifu 500-8513, Japan. 
      tsuyomukai@yahoo.co.jp.
FAU - Shimizu, Masahito
AU  - Shimizu M
AD  - First Department of Internal Medicine, Gifu University Hospital, 1-1 Yanagido, 
      Gifu 501-1194, Japan. shimim-gif@umin.ac.jp.
LA  - eng
PT  - Journal Article
DEP - 20190529
PL  - Switzerland
TA  - J Clin Med
JT  - Journal of clinical medicine
JID - 101606588
PMC - PMC6616879
OTO - NOTNLM
OT  - FORFILINOX
OT  - gemcitabine plus nab-paclitaxel
OT  - pancreatic cancer
OT  - second-line chemotherapy
COIS- Naoki Mita, Takuji Iwashita, Shinya Uemura, Kensaku Yoshida, Yuhei Iwasa, 
      Nobuhiro Ando, Keisuke Iwata, Mitsuru Okuno, Tsuyoshi Mukai, and Masahito Shimizu 
      have nothing to declare.
EDAT- 2019/05/31 06:00
MHDA- 2019/05/31 06:01
PMCR- 2019/05/29
CRDT- 2019/06/01 06:00
PHST- 2019/05/01 00:00 [received]
PHST- 2019/05/19 00:00 [revised]
PHST- 2019/05/22 00:00 [accepted]
PHST- 2019/06/01 06:00 [entrez]
PHST- 2019/05/31 06:00 [pubmed]
PHST- 2019/05/31 06:01 [medline]
PHST- 2019/05/29 00:00 [pmc-release]
AID - jcm8060761 [pii]
AID - jcm-08-00761 [pii]
AID - 10.3390/jcm8060761 [doi]
PST - epublish
SO  - J Clin Med. 2019 May 29;8(6):761. doi: 10.3390/jcm8060761.